Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02062931

Enrollment

Registered

2014-02-14

Start date

2012-03-31

Completion date

2016-11-30

Last updated

2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ovarian Failure

Keywords

Primary Infertility, Primary Amenorrhea, Sex Steroid Deficiency, Premature Ovarian Failure (POF)

Brief summary

Stem cells (SC) are the foundation cells for every organ, tissue and cell in the body. They are undifferentiated blank cells that do not yet have a specific function. Under proper conditions, they begin to develop into specialized tissue and organs. They are self-sustaining and can replicate themselves for long periods of time. They have the remarkable potential to develop into many different cell types in the body. They serves as a sort of repair system for the body, they can theoretically divide without limit to replenish other cells as long as the person is still alive. Premature ovarian failure (POF) is the loss of ovarian function in women less than 40 years. It is associated with sex steroid deficiency, amenorrhea, infertility and elevated serum gonadotropins. POF occurs in 1 % of women. In majority of cases the underlying cause is not identified. Management essentially involves hormone replacement and infertility treatment. This work aimed to evaluate the therapeutic potential of Autologous MSC transplantation in women suffering from Premature Ovarian Failure.

Detailed description

Sample of 60 ml is aspirated from the bone marrow of the iliac crest and prepared in the lab and injected in the ovaries through laparoscopy. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.

Interventions

BIOLOGICALStem Cell Preparation and Injection

Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared. Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments . Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Post-menarche female less than 40 years old. * Follicle-stimulating hormone (FSH) more than or equal to 20 IU/L. * Female with normal karyotyping. * Agree to sign the designed consent for the study.

Exclusion criteria

* Pregnancy and lactation. * Autoimmune diseases. * Breast cancer, ovarian cancer. * Female with abnormal karyotyping (e.g. turner syndrome, fragile X syndrome….). * Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs. * Patients with secondary ovarian failure (e.g. hypothalamic causes) * Those with major medical problems such as malignancy, hepatitis, etc.

Design outcomes

Primary

Measure	Time frame	Description
Improvement of Cases	48 Weeks	Decrease in serum FSH level. Elevation in serum estrogen level. Elevation in serum AMH level.

Secondary

Measure	Time frame	Description
Improvement of Cases	48 Weeks	Participants were followed up monthly(Every 4WKs) and Assessed by: Hormonal Assessment. Clinical Assessment. Ultra Sound Assessment. Disappearance of Menopausal Symptoms. Pregnancy rate within 1 year. Miscarriage rate within one year of injection. Long term follow-up for any adverse effect, assessed for one year from injection.

Countries

Egypt

Contacts

Primary ContactYehia Wafa, MD

yehiawafa@hotmail.com+201223101547

Backup ContactSayed Bakry, PhD

sayed.bakry@yahoo.com+201006609978

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026